{"pmid":32376613,"title":"Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025).","text":["Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025).","Cyclophilins play a key role in the lifecycle of coronaviruses. Alisporivir (Debio 025) is a non-immunosuppressive analogue of cyclosporin A with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in VeroE6 cell line, with an EC50 of 0.46+/-0.04 muM. Alisporivir inhibited a post-entry step of the SARS-CoV-2 lifecycle. These results justify that a proof-of-concept Phase 2 trial be rapidly conducted with alisporivir in patients with SARS-CoV-2 infection.","Antimicrob Agents Chemother","Softic, Laurent","Brillet, Rozenn","Berry, Francois","Ahnou, Nazim","Nevers, Quentin","Morin-Dewaele, Margot","Hamadat, Sabah","Bruscella, Patrice","Fourati, Slim","Pawlotsky, Jean-Michel","Ahmed-Belkacem, Abdelhakim","32376613"],"abstract":["Cyclophilins play a key role in the lifecycle of coronaviruses. Alisporivir (Debio 025) is a non-immunosuppressive analogue of cyclosporin A with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in VeroE6 cell line, with an EC50 of 0.46+/-0.04 muM. Alisporivir inhibited a post-entry step of the SARS-CoV-2 lifecycle. These results justify that a proof-of-concept Phase 2 trial be rapidly conducted with alisporivir in patients with SARS-CoV-2 infection."],"journal":"Antimicrob Agents Chemother","authors":["Softic, Laurent","Brillet, Rozenn","Berry, Francois","Ahnou, Nazim","Nevers, Quentin","Morin-Dewaele, Margot","Hamadat, Sabah","Bruscella, Patrice","Fourati, Slim","Pawlotsky, Jean-Michel","Ahmed-Belkacem, Abdelhakim"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376613","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1128/AAC.00876-20","e_drugs":["alisporivir","Cyclosporine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666262687579897856,"score":9.490897,"similar":[{"pmid":32409832,"title":"SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.","text":["SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.","December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called COVID-19, caused by a newly identified coronavirus, SARS-CoV-2. No therapeutic option is available to treat this infection that has already killed more than 235,000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a non-immunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached Phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the lifecycle of many coronaviruses, including SARS-CoV and MERS-CoV, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at-risk of severe forms of SARS-CoV-2 infection.","Clin Infect Dis","Pawlotsky, Jean-Michel","32409832"],"abstract":["December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called COVID-19, caused by a newly identified coronavirus, SARS-CoV-2. No therapeutic option is available to treat this infection that has already killed more than 235,000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a non-immunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached Phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the lifecycle of many coronaviruses, including SARS-CoV and MERS-CoV, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at-risk of severe forms of SARS-CoV-2 infection."],"journal":"Clin Infect Dis","authors":["Pawlotsky, Jean-Michel"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409832","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/cid/ciaa587","e_drugs":["Cyclosporine","alisporivir"],"topics":["Treatment"],"weight":1,"_version_":1666989866087350273,"score":638.6897},{"pmid":32347055,"title":"[Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].","text":["[Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].","Cyclophilin A (CypA) is a widely distributed and highly conserved protein in organisms. It has peptidyl-prolyl cis/trans isomerase activity and is a receptor for cyclosporin A (CsA). Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses. Seven types of coronaviruses are currently known to infect humans, among which SARS-CoV, MERS-CoV, and SARS-CoV-2 are fatal for humans. It is well established that CypA is essential for the replication of various coronaviruses such as SARS-CoV, CoV-229E, CoV-NL63, and FCoV. Additionally, CsA and its derivatives (ALV, NIM811, etc.) have obvious inhibitory effects on a variety of coronaviruses. These results suggest that CypA is a potential antiviral target and the existing drug CsA might be used as an anti-coronavirus drug. At the end of 2019, SARS-CoV-2 raged in China, which seriously theatern human health and causes huge economic lases. In view of this, we describe the effects of CypA on the replication of coronaviruses and the antiviral activities of its inhibitors, which will provide the scientific basis and ideas for the development of antiviral drugs for SARS-CoV-2.","Sheng Wu Gong Cheng Xue Bao","Tian, Lu","Liu, Wenjun","Sun, Lei","32347055"],"abstract":["Cyclophilin A (CypA) is a widely distributed and highly conserved protein in organisms. It has peptidyl-prolyl cis/trans isomerase activity and is a receptor for cyclosporin A (CsA). Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses. Seven types of coronaviruses are currently known to infect humans, among which SARS-CoV, MERS-CoV, and SARS-CoV-2 are fatal for humans. It is well established that CypA is essential for the replication of various coronaviruses such as SARS-CoV, CoV-229E, CoV-NL63, and FCoV. Additionally, CsA and its derivatives (ALV, NIM811, etc.) have obvious inhibitory effects on a variety of coronaviruses. These results suggest that CypA is a potential antiviral target and the existing drug CsA might be used as an anti-coronavirus drug. At the end of 2019, SARS-CoV-2 raged in China, which seriously theatern human health and causes huge economic lases. In view of this, we describe the effects of CypA on the replication of coronaviruses and the antiviral activities of its inhibitors, which will provide the scientific basis and ideas for the development of antiviral drugs for SARS-CoV-2."],"journal":"Sheng Wu Gong Cheng Xue Bao","authors":["Tian, Lu","Liu, Wenjun","Sun, Lei"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347055","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.13345/j.cjb.200049","keywords":["sars-cov-2","coronaviruses","cyclophilin a","cyclosporin a"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Cyclosporine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494960926720,"score":181.6573},{"pmid":32251767,"pmcid":"PMC7127386","title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","text":["Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.","Antiviral Res","Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling","32251767"],"abstract":["An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits."],"journal":"Antiviral Res","authors":["Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251767","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104786","keywords":["abstract","covid-19","emetine","homoharringtonine","lopinavir","remdesivir","ritonavir"],"e_drugs":["remdesivir","Ribavirin","Lopinavir","Emetine","favipiravir","Homoharringtonine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490993115138,"score":165.0146},{"pmid":32382072,"title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.","text":["Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.","The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M(pro)). Here, the X-ray crystal structure of M(pro) in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 muM) and is a promising lead compound to develop new antiviral treatment for COVID-19.","Nat Struct Mol Biol","Jin, Zhenming","Zhao, Yao","Sun, Yuan","Zhang, Bing","Wang, Haofeng","Wu, Yan","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Du, Xiaoyu","Duan, Yinkai","Yu, Jing","Yang, Xiaobao","Yang, Xiuna","Yang, Kailin","Liu, Xiang","Guddat, Luke W","Xiao, Gengfu","Zhang, Leike","Yang, Haitao","Rao, Zihe","32382072"],"abstract":["The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M(pro)). Here, the X-ray crystal structure of M(pro) in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 muM) and is a promising lead compound to develop new antiviral treatment for COVID-19."],"journal":"Nat Struct Mol Biol","authors":["Jin, Zhenming","Zhao, Yao","Sun, Yuan","Zhang, Bing","Wang, Haofeng","Wu, Yan","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Du, Xiaoyu","Duan, Yinkai","Yu, Jing","Yang, Xiaobao","Yang, Xiuna","Yang, Kailin","Liu, Xiang","Guddat, Luke W","Xiao, Gengfu","Zhang, Leike","Yang, Haitao","Rao, Zihe"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382072","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41594-020-0440-6","e_drugs":["1-hexylcarbamoyl-5-fluorouracil"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666419683280027650,"score":140.45364},{"pmid":32120929,"pmcid":"PMC7175275","title":"Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63.","text":["Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63.","Strobilanthes cusia (Nees) Kuntze is a Chinese herbal medicine used in the treatment of respiratory virus infections. The methanol extract of S. cusia leaf contains chemical components such as beta-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities. However, the antiviral action of S. cusia leaf and its components against human coronavirus remains to be elucidated. Human coronavirus NL63 infection is frequent among immunocompromised individuals, young children, and in the elderly. This study investigated the anti-Human coronavirus NL63 (HCoV-NL63) activity of the methanol extract of S. cusia leaf and its major components. The methanol extract of S. cusia leaf effectively inhibited the cytopathic effect (CPE) and virus yield (IC50 = 0.64 mug/mL) in HCoV-NL63-infected cells. Moreover, this extract potently inhibited the HCoV-NL63 infection in a concentration-dependent manner. Among the six components identified in the methanol extract of S. cusia leaf, tryptanthrin and indigodole B (5aR-ethyltryptanthrin) exhibited potent antiviral activity in reducing the CPE and progeny virus production. The IC50 values against virus yield were 1.52 muM and 2.60 muM for tryptanthrin and indigodole B, respectively. Different modes of time-of-addition/removal assay indicated that tryptanthrin prevented the early and late stages of HCoV-NL63 replication, particularly by blocking viral RNA genome synthesis and papain-like protease 2 activity. Notably, tryptanthrin (IC50 = 0.06 muM) and indigodole B (IC50 = 2.09 muM) exhibited strong virucidal activity as well. This study identified tryptanthrin as the key active component of S. cusia leaf methanol extract that acted against HCoV-NL63 in a cell-type independent manner. The results specify that tryptanthrin possesses antiviral potential against HCoV-NL63 infection.","Biomolecules","Tsai, Yu-Chi","Lee, Chia-Lin","Yen, Hung-Rong","Chang, Young-Sheng","Lin, Yu-Ping","Huang, Su-Hua","Lin, Cheng-Wen","32120929"],"abstract":["Strobilanthes cusia (Nees) Kuntze is a Chinese herbal medicine used in the treatment of respiratory virus infections. The methanol extract of S. cusia leaf contains chemical components such as beta-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities. However, the antiviral action of S. cusia leaf and its components against human coronavirus remains to be elucidated. Human coronavirus NL63 infection is frequent among immunocompromised individuals, young children, and in the elderly. This study investigated the anti-Human coronavirus NL63 (HCoV-NL63) activity of the methanol extract of S. cusia leaf and its major components. The methanol extract of S. cusia leaf effectively inhibited the cytopathic effect (CPE) and virus yield (IC50 = 0.64 mug/mL) in HCoV-NL63-infected cells. Moreover, this extract potently inhibited the HCoV-NL63 infection in a concentration-dependent manner. Among the six components identified in the methanol extract of S. cusia leaf, tryptanthrin and indigodole B (5aR-ethyltryptanthrin) exhibited potent antiviral activity in reducing the CPE and progeny virus production. The IC50 values against virus yield were 1.52 muM and 2.60 muM for tryptanthrin and indigodole B, respectively. Different modes of time-of-addition/removal assay indicated that tryptanthrin prevented the early and late stages of HCoV-NL63 replication, particularly by blocking viral RNA genome synthesis and papain-like protease 2 activity. Notably, tryptanthrin (IC50 = 0.06 muM) and indigodole B (IC50 = 2.09 muM) exhibited strong virucidal activity as well. This study identified tryptanthrin as the key active component of S. cusia leaf methanol extract that acted against HCoV-NL63 in a cell-type independent manner. The results specify that tryptanthrin possesses antiviral potential against HCoV-NL63 infection."],"journal":"Biomolecules","authors":["Tsai, Yu-Chi","Lee, Chia-Lin","Yen, Hung-Rong","Chang, Young-Sheng","Lin, Yu-Ping","Huang, Su-Hua","Lin, Cheng-Wen"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32120929","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.3390/biom10030366","keywords":["strobilanthes cusia","antiviral","human coronavirus nl63","indigodole b","tryptanthrin","virucidal"],"locations":["Chinese","indirubin","tryptanthrin","betulin","tryptanthrin"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tryptanthrine","indirubin","gamma-sitosterol","Methanol","betulin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490735165441,"score":139.55151}]}